Instrument Inactif

Communiqués SCHERING-PLOUGH

Actions

SGP

US8066051017

Produits pharmaceutiques

Cours en clôture NYSE Autres places de cotation
- ^USD	-

22/10/09	SCHERING-PLOUGH : troisième trimestre en ligne avec les attentes
22/10/09	Schering-Plough : BPA ajusté stable au 3e trimestre.

Communiqués

02/11/09	SCHERING-PLOUGH : Announces Sponsorship of Rabies-Control Projects in India	PR
02/11/09	SCHERING-PLOUGH : Investigational Sublingual Allergy Immunotherapy Tablet Meets Primary Endpoint in a Study of Adult Subjects With a History of Grass Pollen Allergies	PR
30/10/09	SCHERING-PLOUGH : U.S. Food and Drug Administration Issues Complete Response Letter Regarding PEGINTRON(R) for Malignant Melanoma	PR
29/10/09	SCHERING-PLOUGH : Standard & Poor's Announces Changes to U.S. Indices	PR
22/10/09	SCHERING-PLOUGH : Reports Financial Results for 2009 Third Quarter	PR
13/10/09	SCHERING-PLOUGH : Nobilon Advances Intranasal Seasonal Influenza Vaccine Into Proof of Concept Study	PR
12/10/09	SCHERING-PLOUGH : Schedules Conference Call Webcast For 2009 Third Quarter Earnings	PR
06/10/09	SCHERING-PLOUGH : SIMPONI(TM) (golimumab) Receives European Approval as Once-Monthly Subcutaneous Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis with Novel SmartJect(TM) Autoinjector	PR
18/09/09	SCHERING-PLOUGH : Declares Quarterly Dividends on Common Shares and Mandatory Convertible Preferred Stock	PR
14/09/09	SCHERING-PLOUGH : Reports Long-Term Vicriviroc Data From Phase II Open-Label Extension Study in Treatment-Experienced HIV-Infected Patients	PR
14/09/09	SCHERING-PLOUGH : Reports Data From SAPHRIS(R) (asenapine) Long-Term Schizophrenia Relapse Prevention Study	PR
01/09/09	SCHERING-PLOUGH : New Non-Drowsy CLARITIN(R) 12-Hour Gets Allergy Sufferers Through Their Busy Day	PR
26/08/09	SCHERING-PLOUGH : Announces Two European Filings	PR
14/08/09	SCHERING-PLOUGH : ANNOUNCES FDA APPROVAL OF SAPHRIS(R) (asenapine): for acute treatment of schizophrenia in adults and manic or mixed episodes of bipolar I disorder with or without psychotic features in adults	PR
14/08/09	SCHERING-PLOUGH : Video: Schering-Plough Announces FDA Approval of SAPHRIS(R) (asenapine) for Acute Treatment of Schizophrenia In Adults and Manic or Mixed Episodes of Bipolar I Disorder With or Without Psychotic Features In Adults	PR
12/08/09	SCHERING-PLOUGH : Announces Resolution of Litigations on U.S. Marketing of Generic Forms of Solid Oral Dosage Forms of CLARINEX(R)	PR
11/08/09	SCHERING-PLOUGH : Photos: New CLARITIN(R) Eye Relieves Itchy Eyes For Up To 12 Hours	PR
10/08/09	SCHERING-PLOUGH : PTC Therapeutics Announces Achievement of Major Milestone in Schering-Plough Hepatitis C Collaboration	PR
07/08/09	SCHERING-PLOUGH : Shareholders Approve Merger With Merck	PR
06/08/09	SCHERING-PLOUGH : to Webcast Special Meeting of Shareholders	PR
05/08/09	SCHERING-PLOUGH : Hagens Berman Sobol Shapiro: Vytorin and Zetia Makers Settle Class-Action Suit With Proposed $41.5 Million	PR
30/07/09	SCHERING-PLOUGH : /C O R R E C T I O N -- Schering-Plough Corporation/	PR
24/07/09	SCHERING-PLOUGH : Reports Proposed Settlement in Litigation Involving Planned Merger with Merck	PR
21/07/09	SCHERING-PLOUGH : Reports Financial Results for 2009 Second Quarter	PR
15/07/09	SCHERING-PLOUGH : Expands Vicriviroc Phase II Study in Treatment-Naive Patients With HIV	PR